RNF170 (Q-17): sc-98115



The Power to Question

BACKGROUND

The RING-type zinc finger motif is present in a number of viral and eukaryotic proteins and is made of a conserved cysteine-rich domain that is able to bind two zinc atoms. Proteins that contain this conserved domain are generally involved in the ubiquitination pathway of protein degradation. RNF170 (RING finger protein 170), also known as putative LAG1-interacting protein, FLJ38306 or DKF2p564A022, is a 258 amino acid multi-pass membrane protein containing one RING-type zinc finger. Five RNF170 isoforms are known to exist as a result of alternative splicing, and the gene encoding RNF170 maps to human chromosome 8p11.21. Consisting of nearly 146 million base pairs, chromosome 8 encodes over 800 genes and is associated with a variety of diseases and malignancies. Schizophrenia, bipolar disorder, trisomy 8, Pfeiffer syndrome, congenital hypothyroidism, Waardenburg syndrome and some leukemias and lymphomas are thought to occur as a result of defects in specific genes that maps to chromosome 8.

REFERENCES

- Borden, K.L. and Freemont, P.S. 1996. The RING finger domain: a recent example of a sequence-structure family. Curr. Opin. Struct. Biol. 6: 395-401.
- Lorick, K.L., et al. 1999. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc. Natl. Acad. Sci. USA 96: 11364-11369.
- 3. Kashino, G., et al. 2001. Preferential expression of an intact WRN gene in Werner syndrome cell lines in which a normal chromosome 8 has been introduced. Biochem. Biophys. Res. Commun. 289: 111-115.
- Selicorni, A., et al. 2002. Cytogenetic mapping of a novel locus for type II Waardenburg syndrome. Hum. Genet. 110: 64-67.
- McQueen, M.B., et al. 2005. Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6g and 8g. Am. J. Hum. Genet. 77: 582-595.
- Mossafa, H., et al. 2006. Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis. Leuk. Lymphoma 47: 1885-1893.
- Agrelo, R., et al. 2006. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc. Natl. Acad. Sci. USA 103: 8822-8827.

CHROMOSOMAL LOCATION

Genetic locus: RNF170 (human) mapping to 8p11.21; Rnf170 (mouse) mapping to 8 A2.

SOURCE

RNF170 (Q-17) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of RNF170 of human origin.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PRODUCT

Each vial contains 200 μg IgG in 1.0 ml of PBS with <0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-98115 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

Available as TransCruz reagent for Gel Supershift and ChIP applications, sc-98115 X, $100 \mu g/0.1 \text{ ml}$.

APPLICATIONS

RNF170 (Q-17) is recommended for detection of RNF170 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with RNF170-2, RNF170-3, RNF170-5.

RNF170 (Q-17) is also recommended for detection of RNF170 in additional species, including equine, canine, bovine, porcine and avian.

Suitable for use as control antibody for RNF170 siRNA (h): sc-77659, RNF170 siRNA (m): sc-153026, RNF170 shRNA Plasmid (h): sc-77659-SH, RNF170 shRNA Plasmid (m): sc-153026-SH, RNF170 shRNA (h) Lentiviral Particles: sc-77659-V and RNF170 shRNA (m) Lentiviral Particles: sc-153026-V.

RNF170 (Q-17) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.

Molecular Weight (predicted) of RNF170: 29 kDa.

Molecular Weight (observed) of RNF170: 42 kDa.

Positive Controls: HeLa whole cell lysate: sc-2200, Hep G2 cell lysate: sc-2227 or Jurkat whole cell lysate: sc-2204.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 **Europe** +00800 4573 8000 49 6221 4503 0 **www.scbt.com**